Sampling Uncertainty and Cost-Effectiveness Analysis (Part 1a)

Henry A. Glick, Ph.D.

EPI 550

April 17, 2020



Confidence About Value for the Cost

- Common goal of economic analysis: identify when we can be confident that a therapy is good value compared to another
- Threat to confidence: economic result observed in experiment may not reflect result in the population
 Single sample drawn from population
- Referred to as sampling (or stochastic) uncertainty
- Methods for estimating sampling uncertainty for
- economic outcomes have much in common with methods used for clinical findings – But there are ways that they differ





Outline

- Familiarize you with methods used in literature to identify when we can and cannot be confident about a therapy's value
 - Cost-effectiveness plane
 - Acceptability curves
 - CI for ICER
 - CI for NMB
 - Value of information
- Goal: demonstrate quantification and interpretation of sampling uncertainty using these methods


 Including where people have gone wrong
- · Don't focus on technical aspects of estimation












Information from Plane

- Cost-effectiveness plane provides information about point estimates, confidence intervals and p-values for:
 - Difference in effect
 - Difference in cost
 - Cost-effectiveness analysis






Red and blue (because all of their densities fall on one side of 0 on Y-axis)

Black triangles not significantly different (because too large a density falls on each side of 0 on Y-axis)









Red and blue (because all of their densities fall on one side of 0 on X-axis)

Black triangles not significantly different (because too large a density falls on each side of 0 on X axis)












Red, blue, and cyan (because all of their densities fall on one side of WTP)

Black triangles not confident because large fractions of density fall on both sides of WTP








For cyan, confident of dominance (because all of density falls below X-axis and to right of Y-axis)

For blue, confident of good value (because all of density falls above x axis, to right of y axis, and below WTP line

For red, confident of bad value (because all of density falls above x axis, to right of y axis, and above WTP line)






Can't be confident about difference in cost (because too large a density above and below X-axis)

Can't be confident about difference in effect (because too large a density to the left and right of Y-axis)

Can be confident of cost-effectiveness (because all density below WTP line)








Provide a statistic that allows decision makers to determine if – based on their own WTP – they can be confident of value



Confidence Intervals

- Graphs above provide examples of 0 (for differences in means, including NMB), 1 (for OR and RR), or willingness to pay (W) (for CI for CER) falling either well inside or fully outside distribution of results
- Don't typically require that results be fully outside distribution to conclude they significantly differ from 0, 1, or W
 - Parametrically never happens
- Usual strategy: Identify a tolerance e.g., 2.5% for 95% confidence or 5% for 90% confidence for the maximum fraction of results that can fall on one side of 0, 1, or W
- Conclude with 95% confidence that result excludes 0, 1, or W if 0, 1, or W fall outside 95% Cl








Can be 95% confident of a difference for red and blue (because 0 on X-axis does not fall within the 95% CI)

Can't be 95% confident of difference for black triangles (because 0 on X-axis falls within 95% CI)








Can be 95% confident of a difference for red and blue (because 0 on Y-axis does not fall within the 95% CI)

Can't be 95% confident of difference for black triangles (because 0 on Y-axis falls within 95% CI)







95% CI


Upper left: CI for ΔC

Upper right: 95% confidence ellipse (CE) around the point on the C/E plane defined by ΔC and Δq (CE for point, not CI for ICER)

Lower right: CI for NMB


Lower left: 95% CI for the ICER










For Which Values of W...? Confident of bad value for values of W between 0 (X-axis) and lower right line Confident of good value for values of W between upper left line and ∞ (Y-axis) Not confident therapies differ in value for values of W between the lower right line and the upper left line


















Sampling Uncertainty Issues

- # of methods available for expressing uncertainty
 - Acceptability curve
 - CI for ICER
 - CI for NMB
 - Value of information
- What is threshold, maximum willingness to pay?
 - Differs across jurisdictions
 - Differs within jurisdictions
- Should we be 95% confident?
 - A lot of economists claim not




First Example: (Nonparametrically) all replicates on one side of Y-axis and naïve ordering works (easiest case)




Experiment 1

- Therapy A vs Therapy B (A B)
- Δcost = 1000 (SE: 324.9, p=0.002)
- ΔQALYs = 0.01 (SE: 0.001925, p=0.000)
- A is significantly more costly and significantly more effective
 - CER = 1000 / 0.01 = 100,000 / QALY gained
- · 250 participants in each arm of the trial
- Correlation between difference in cost and effect is
 -0.71015









"Counting" Method 1: Acceptability Curve

- Previously said usually identify a tolerance e.g., 2.5% for 95% confidence – for the maximum fraction of results that can fall on one side of 0, 1, or W
- Can determine fraction that falls on one side of W by counting / estimating density of results distribution falling on each side of W
- · Referred to as acceptability curve



Parametric or Nonparametric Construction


- · Can be constructed nonparametrically or parametrically
- Nonparametric construction usually derived by counting bootstrap/second order Monte Carlo replicates
 - Does not assume bivariate normality
 - Particularly for acceptability curve and CI for CER, calculating fraction falling on each side of exact same lines through origin
- Parametric construction generally based on (rearrangement of) Fieller's theorem formula for CI for CER (i.e., transformation of same formula)
 - Assumes difference in costs and effects distributed bivariate normal



Acceptability Curve

- Acceptability criterion defined on cost-effectiveness plane as a line passing through origin with slope equal to WTP
- When applied to positive values of WTP, proportion of distribution of difference in cost and effect below and to right of line is "acceptable" (i.e., has positive NMB)
 - Proportion acceptable for one therapy = proportion unacceptable for alternative therapy
- Proportion above and to left of line is "unacceptable"
 Proportion unacceptable for one therapy = proportion acceptable for alternative therapy









Counting Methods


- When all replicates are on one side of Y-axis, one can:
 Calculate ratios and count ratios ≤ WTP
- Whether or not all replicates are on one side of the Y-axis, one can:
 - Calculate NMB using WTP; count values of NMB \geq 0 - Calculate MB for each Rx using WTP; count
 - replicates for which Rx A's MB greater than Rx B's


























W	What is often said
28,200	"97.5% chance Rx A not good value" (Rx B good value)
76,800	"70% chance Rx A not good value"
100,000	"50% chance either therapy good value"
127,700	"70% chance Rx A good value" (Rx B not good value
245,200	"97.5% chance Rx A good value"
curve Ignores f 	to adopt 1-tailed interpretation of acceptability act that 50% – not 0% – represents no on for distinguishing between therapies



2-tailed Confidence Statements

- Two-tailed confidence statements
 - (For heights > 0.5) Confidence level:

(2 * Height) - 1

- e.g., if height of curve is 0.975 for W = 50,000, (2 * .975) -1 = "95% confident that therapy is acceptable / cost-effective"
- (For heights < 0.5) Confidence level:

1-(2*Height)

 e.g., if height of curve is 0.025 for W = 50,000, "95% confident alternative therapy is acceptable / cost-effective"



